Andrew Murphy

Executive Vice President, Research and Co-Chief Scientific Officer · Regeneron Pharmaceuticals

Biopharmaceuticals

Andrew Murphy is executive vice president of research and co-chief scientific officer of Regeneron Pharmaceuticals. He joined in 1999 as director of genomics and bioinformatics and is a co-inventor of the company’s VelociGene and VelocImmune technologies.

Last reviewed: Oct 21, 2026

Andrew Murphy

Executive Vice President, Research and Co-Chief Scientific Officer Regeneron Pharmaceuticals

Last Reviewed: October 21, 2026

Executive Summary

Andrew Murphy is executive vice president of research and co-chief scientific officer of Regeneron Pharmaceuticals. He joined in 1999 as director of genomics and bioinformatics and is a co-inventor of the company’s VelociGene and VelocImmune technologies.

Career Highlights

  • Joined Regeneron in 1999 as director of genomics and bioinformatics.
  • Became co-chief scientific officer in January 2026.
  • Is a co-inventor of VelociGene and VelocImmune.

Professional Journey

Murphy worked at Cadus Pharmaceuticals for seven years before joining Regeneron in 1999 as director of Genomics and Bioinformatics. At Regeneron, he led the Gene Discovery and Bioinformatics and Target Discovery groups.

He is a co-inventor of VelociGene and VelocImmune, two of the company’s research technologies. His responsibilities have continued to include technology centers and therapeutic focus areas.

In January 2026, he became co-chief Scientific Officer while continuing as executive vice president of Research. His progression reflects a career within the company spanning computational and genomic research, technology invention and broader scientific leadership.

Education

Murphy earned a BS in molecular biology from the University of Wisconsin and a PhD in human genetics from Columbia University’s College of Physicians and Surgeons.